vs

Side-by-side financial comparison of BEASLEY BROADCAST GROUP INC (BBGI) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

BEASLEY BROADCAST GROUP INC is the larger business by last-quarter revenue ($53.1M vs $33.4M, roughly 1.6× Ginkgo Bioworks Holdings, Inc.). On growth, BEASLEY BROADCAST GROUP INC posted the faster year-over-year revenue change (-21.2% vs -23.8%). BEASLEY BROADCAST GROUP INC produced more free cash flow last quarter ($-4.4M vs $-47.7M). Over the past eight quarters, BEASLEY BROADCAST GROUP INC's revenue compounded faster (-1.2% CAGR vs -6.2%).

Beasley Broadcast Group, Inc., based in Naples, Florida, is an owner/operator of radio stations in the United States. As of September 2025, the company owns 54 stations under the Beasley Media Group name.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BBGI vs DNA — Head-to-Head

Bigger by revenue
BBGI
BBGI
1.6× larger
BBGI
$53.1M
$33.4M
DNA
Growing faster (revenue YoY)
BBGI
BBGI
+2.7% gap
BBGI
-21.2%
-23.8%
DNA
More free cash flow
BBGI
BBGI
$43.3M more FCF
BBGI
$-4.4M
$-47.7M
DNA
Faster 2-yr revenue CAGR
BBGI
BBGI
Annualised
BBGI
-1.2%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBGI
BBGI
DNA
DNA
Revenue
$53.1M
$33.4M
Net Profit
$-190.1M
Gross Margin
Operating Margin
-433.6%
-211.9%
Net Margin
-358.4%
Revenue YoY
-21.2%
-23.8%
Net Profit YoY
-9136.7%
EPS (diluted)
$-105.71
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBGI
BBGI
DNA
DNA
Q4 25
$53.1M
$33.4M
Q3 25
$51.0M
$38.8M
Q2 25
$53.0M
$49.6M
Q1 25
$48.9M
$48.3M
Q4 24
$67.3M
$43.8M
Q3 24
$58.2M
$89.0M
Q2 24
$60.4M
$56.2M
Q1 24
$54.4M
$37.9M
Net Profit
BBGI
BBGI
DNA
DNA
Q4 25
$-190.1M
Q3 25
$-3.6M
$-80.8M
Q2 25
$-154.2K
$-60.3M
Q1 25
$-2.7M
$-91.0M
Q4 24
$-2.1M
Q3 24
$-3.6M
$-56.4M
Q2 24
$-276.0K
$-217.2M
Q1 24
$8.0K
$-165.9M
Operating Margin
BBGI
BBGI
DNA
DNA
Q4 25
-433.6%
-211.9%
Q3 25
-1.1%
-231.8%
Q2 25
5.5%
-132.1%
Q1 25
-4.1%
-184.1%
Q4 24
11.3%
-236.3%
Q3 24
2.1%
-62.0%
Q2 24
8.9%
-396.7%
Q1 24
-2.0%
-469.1%
Net Margin
BBGI
BBGI
DNA
DNA
Q4 25
-358.4%
Q3 25
-7.0%
-207.9%
Q2 25
-0.3%
-121.6%
Q1 25
-5.5%
-188.2%
Q4 24
-3.1%
Q3 24
-6.1%
-63.3%
Q2 24
-0.5%
-386.4%
Q1 24
0.0%
-437.3%
EPS (diluted)
BBGI
BBGI
DNA
DNA
Q4 25
$-105.71
$-1.41
Q3 25
$-1.97
$-1.45
Q2 25
$-0.09
$-1.10
Q1 25
$-1.50
$-1.68
Q4 24
$-1.23
$-1.91
Q3 24
$-2.33
$-1.08
Q2 24
$-0.18
$-4.23
Q1 24
$0.01
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBGI
BBGI
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$9.9M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-49.3M
$508.6M
Total Assets
$299.3M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBGI
BBGI
DNA
DNA
Q4 25
$9.9M
$422.6M
Q3 25
$14.3M
$495.5M
Q2 25
$13.7M
$559.4M
Q1 25
$12.2M
$325.3M
Q4 24
$13.8M
$561.6M
Q3 24
$27.8M
$616.2M
Q2 24
$33.3M
$730.4M
Q1 24
$27.8M
$840.4M
Total Debt
BBGI
BBGI
DNA
DNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$247.1M
Q3 24
$265.2M
Q2 24
$264.9M
Q1 24
$264.5M
Stockholders' Equity
BBGI
BBGI
DNA
DNA
Q4 25
$-49.3M
$508.6M
Q3 25
$141.0M
$559.8M
Q2 25
$144.5M
$613.0M
Q1 25
$144.6M
$647.4M
Q4 24
$147.2M
$716.1M
Q3 24
$145.8M
$797.9M
Q2 24
$149.1M
$833.1M
Q1 24
$149.1M
$987.3M
Total Assets
BBGI
BBGI
DNA
DNA
Q4 25
$299.3M
$1.1B
Q3 25
$534.6M
$1.2B
Q2 25
$548.0M
$1.2B
Q1 25
$539.3M
$1.3B
Q4 24
$549.2M
$1.4B
Q3 24
$571.5M
$1.5B
Q2 24
$573.2M
$1.6B
Q1 24
$566.3M
$1.6B
Debt / Equity
BBGI
BBGI
DNA
DNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.68×
Q3 24
1.82×
Q2 24
1.78×
Q1 24
1.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBGI
BBGI
DNA
DNA
Operating Cash FlowLast quarter
$-3.2M
$-47.7M
Free Cash FlowOCF − Capex
$-4.4M
$-47.7M
FCF MarginFCF / Revenue
-8.3%
-142.8%
Capex IntensityCapex / Revenue
2.3%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-13.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBGI
BBGI
DNA
DNA
Q4 25
$-3.2M
$-47.7M
Q3 25
$-4.9M
$-31.6M
Q2 25
$3.1M
$-40.3M
Q1 25
$-3.5M
$-51.5M
Q4 24
$-1.5M
$-42.4M
Q3 24
$-4.8M
$-103.5M
Q2 24
$6.6M
$-84.4M
Q1 24
$-4.0M
$-89.3M
Free Cash Flow
BBGI
BBGI
DNA
DNA
Q4 25
$-4.4M
$-47.7M
Q3 25
$-7.1M
Q2 25
$2.5M
$-40.3M
Q1 25
$-4.3M
$-59.1M
Q4 24
$-1.9M
$-56.1M
Q3 24
$-5.4M
$-118.6M
Q2 24
$5.6M
$-111.4M
Q1 24
$-5.0M
$-96.0M
FCF Margin
BBGI
BBGI
DNA
DNA
Q4 25
-8.3%
-142.8%
Q3 25
-14.0%
Q2 25
4.7%
-81.2%
Q1 25
-8.7%
-122.4%
Q4 24
-2.8%
-128.0%
Q3 24
-9.3%
-133.2%
Q2 24
9.2%
-198.2%
Q1 24
-9.2%
-252.9%
Capex Intensity
BBGI
BBGI
DNA
DNA
Q4 25
2.3%
0.0%
Q3 25
4.4%
0.0%
Q2 25
1.1%
0.1%
Q1 25
1.6%
15.8%
Q4 24
0.6%
31.3%
Q3 24
1.1%
16.9%
Q2 24
1.7%
48.1%
Q1 24
1.7%
17.7%
Cash Conversion
BBGI
BBGI
DNA
DNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-506.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBGI
BBGI

Audio Advertising$40.5M76%
Digital Advertising$12.6M24%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons